Microbiome–Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma
Collectively, microbiome-based approaches may contribute to the development of personalized immunotherapeutic strategies in HCC, although larger standardized prospective studies are required before microbiome-derived biomarkers can be implemented in routine clinical practice.